Happy Solstice Day!
As we wind up this week, I am already looking forward to the exciting event next week, right here in San Diego – 2014 BIO International Convention, the “world’s largest biotechnology gathering”. I will be blogging from BIO2014, though it has been hard to decide which sessions to write about because there are so many good ones to choose from. Stay tuned!
Here’s a roundup of articles and news on science, medicine, and policy from this week.
This week I blogged about high diversity of cells in glioblastoma – a brain cancer with extremely poor prognosis. RNA sequencing (RNA-seq) or transcriptomics of single cells from patient tumors was able to identify a highly heterogeneous population of cells in a tumor. This has implications for glioblastoma diagnosis and therapy. You can read more on my blog RNA-seq reveals glioblastoma heterogeneity.
Science and Medicine
The human immunodeficiency virus, aka HIV is notoriously difficult to eliminate from the body with drug therapy. This is at least in part because this virus can hide in the body. One way around it is to try and make the virus “announce” where it is. For this, in a recent study published in Science, scientists tried increasing the variation in the gene expression of the virus. In other words, they increased its “noise”, which in turn reactivated the latent, hidden HIV. This form of the virus is more sensitive to drugs.
The first precision medicine trial from the National Clinical Trials Network, Lung-MAP was launched. This trial will be conducted under a public-private collaboration. This trial is a multi-drug, biomarker-driven clinical trial for patients with advanced squamous cell lung cancer.
Takeda Pharmaceutical has voluntarily decided to end the development program for its investigational compound, orteronel (TAK-700). This is a nonsteroidal, selective inhibitor of 17,20-lyase that was being tested for prostate cancer. Orteronel was unable to extend overall survival in patients in phase III clinical trials.
Increasing advances in the microbiome research have revealed that the composition of microbiota in the gut can play an important role in the development of metabolic disorders. A recent study now shows that the diabetic drug, metformin can modulate the gut microbiome and in turn lead to better control of blood sugar.
The FDA is taking social media seriously as well. And it is about time. As a testament to this fact, the FDA has now proposed specific rules for listing risks on social media platforms.
Qiagen received FDA approval for CMV RGQ MDx Kit for human cytomegalovirus (CMV) – an assay that can allow rapid quantification of CMV DNA in patient samples, an important test for transplant patients.
The European Medicines Agency (EMA) has announced that it is relaxing data-sharing rules to enable clinical trials data to undergo public scrutiny.
The life sciences company Sequenom Laboratories is now collaborating with Quest Diagnostics. As part of this collaboration, Quest is set to offer national access to Sequenom’s MaterniT21 PLUS test. This test analyzes chromosomal material in cell-free fetal DNA of pregnant women and can help diagnose fetal chromosomal abnormalities.
It is the age of mergers and acquisitions. Now an academic institute is getting in on the game. University of Southern California is in discussions to possible acquire or merge with the Scripps Research Institute.
So let’s call it a week. See you back next week with lots of exciting news from BIO2014.